Three-year treatment outcomes of Aflibercept versus Ranibizumab for diabetic macular edema:: Data from the Fight Retinal Blindness! Registry
In: Gabrielle, Pierre-Henry; Nguyen, Vuong; Creuzot-Garcher, Catherine; Arnold, Jennifer J; Mehta, Hemal; Duran, Mónica Asencio; Bougamha, Walid; Carreño, Ester; Viola, Francesco; Squirrell, David; Barthelmes, Daniel; Gillies, Mark (2022). Three-year treatment outcomes of Aflibercept versus Ranibizumab for diabetic macular edema:: Data from the Fight Retinal Blindness! Registry. Retina, 42(6):1085-1094, 2022
Online
academicJournal
Zugriff:
PURPOSE Compare the 3-year outcomes of ranibizumab versus aflibercept in eyes with diabetic macular edema in daily practice. METHODS This was a retrospective analysis of naive diabetic macular edema eyes starting intravitreal injections of ranibizumab (0.5 mg) or aflibercept (2 mg) from January 1, 2013 to December 31, 2017 that were collected in the Fight Retinal Blindness! Registry. RESULTS We identified 534 eyes (ranibizumab-267 and aflibercept-267) of 402 patients. The adjusted mean (95% confidence interval) visual acuity change of +1.3 (-0.1 to 4.2) letters in the ranibizumab group and +2.4 (-0.2 to 5.1) letters (P = 0.001) in the aflibercept group at 3 years was not clinically different. However, the adjusted mean CST change seemed to remain significantly different throughout the 3-year period with higher reductions in favor of aflibercept (-87.8 [-108.3 to -67.4] µm for ranibizumab vs. -114.4 [-134.4 to -94.3] for aflibercept; P < 0.01). When baseline visual impairment was moderate (visual acuity ≤68 Early Treatment Diabetic Retinopathy Study letters), we found a faster improvement in visual acuity in eyes treated with aflibercept up until 18 months of treatment than eyes treated with ranibizumab, which then stayed similar until 36 months of treatment, whereas there was no apparent difference when baseline visual impairment was mild (visual acuity ≥69 Early Treatment Diabetic Retinopathy Study letters). The rate of serious adverse events was low. CONCLUSION Aflibercept and ranibizumab were both effective and safe for diabetic macular edema over 3 years.
Titel: |
Three-year treatment outcomes of Aflibercept versus Ranibizumab for diabetic macular edema:: Data from the Fight Retinal Blindness! Registry
|
---|---|
Autor/in / Beteiligte Person: | Gabrielle, Pierre-Henry ; Nguyen, Vuong ; Creuzot-Garcher, Catherine ; Arnold, Jennifer J ; Mehta, Hemal ; Duran, Mónica Asencio ; Bougamha, Walid ; Carreño, Ester ; Viola, Francesco ; Squirrell, David ; Barthelmes, Daniel ; Gillies, Mark |
Link: | |
Zeitschrift: | Gabrielle, Pierre-Henry; Nguyen, Vuong; Creuzot-Garcher, Catherine; Arnold, Jennifer J; Mehta, Hemal; Duran, Mónica Asencio; Bougamha, Walid; Carreño, Ester; Viola, Francesco; Squirrell, David; Barthelmes, Daniel; Gillies, Mark (2022). Three-year treatment outcomes of Aflibercept versus Ranibizumab for diabetic macular edema:: Data from the Fight Retinal Blindness! Registry. Retina, 42(6):1085-1094, 2022 |
Veröffentlichung: | Lippincott Williams & Wilkins, 2022 |
Medientyp: | academicJournal |
ISSN: | 0275-004X (print) |
DOI: | 10.5167/uzh-220298 |
Schlagwort: |
|
Sonstiges: |
|